While the dollar amount is small relative to market cap, the concentration of sales among C-suite executives, especially the CEO and CFO, warrants attention. Monitor for follow-up filings or commentary around earnings or pipeline updates. Absent negative news, this is likely routine portfolio management, but the pattern should not be ignored if repeated.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 6 $559.65entry
- T+1 · 7mo ago +1.08%α +1.04% · $565.70
- T+5 · 7mo ago +3.21%α −0.91% · $577.63
- T+20 · 7mo ago +3.85%α −5.11% · $581.22
- T+60 · 5mo ago −2.23%α −15.41% · $547.15
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three corporate insiders at United Therapeutics, including CEO Martine Rothblatt and CFO James Edgemond, conducted open-market sales totaling $1.08 million over a 7-day window, following a series of derivative exercises. The sales are modest in absolute value but involve key executives, raising questions about intent despite no clear signs of distress.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt sold 1,300 shares for $725K in open-market transactions across multiple days (April 6–9, 2026).
- CFO James Edgemond sold 680 shares for $388K, including a $322K sale on April 9.
- EVP & General Counsel Paul Mahon sold 514 shares for $288K on April 2.
- Total open-market sales: $1.08M, representing 0.0043% of the company's $25.2B market cap.
- Multiple non-cash derivative exercises occurred concurrently, accounting for the majority of transaction volume but $0 economic outflow.
Financial Impact
$1.08 million in net open-market selling by insiders
Risk Factors
- Perception of insider skepticism if sales continue or accelerate in next quarter
- Potential misinterpretation of derivative exercises as selling pressure when they are non-cash events
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1775853196702 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers